Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Watkins

Occupational Medicine Nashville, TN Medical Doctor

NPI 1972641074 CMS profile 647213

315 14Th Ave N, Nashville, TN 37203

Open in the dashboard

General payments

$1,352

24 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$243,458 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Marc Watkins of Nashville, TN is reported in the CMS Open Payments database as having received $1,352 across 24 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $243,458 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Occupational Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $357 5
2024 General $295 6
2023 General $323 5
2022 General $315 5
2021 General $18 1
2019 General $45 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Watkins
  • Occupational Medicine median
  • Middle half of Occupational Medicine
  • National median

In program year 2025, general payments to Marc Watkins were reported at $357. Among 219 Occupational Medicine profiles paid that year, the median was $54 and the middle half received between $24 and $162.

Show as a table
Year Marc Watkins Occupational Medicine median Middle half National median
2019 $45 $59 $18–$204 $163
2020 $0 $49 $21–$288 $114
2021 $18 $56 $22–$204 $132
2022 $315 $83 $24–$209 $149
2023 $323 $71 $25–$185 $160
2024 $295 $77 $26–$205 $164
2025 $357 $54 $24–$162 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $677 14 payments
  2. Novo Nordisk Inc $569 6 payments
  3. Pfizer Inc. $67 2 payments
  4. Genentech USA, Inc. $20 1 payment
  5. Merge Healthcare Incorporated $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,352 24 payments
Products named General payments · program years 2019–2025
  1. Wegovy $72 2 payments
  2. Saxenda $72 2 payments
  3. NEXPLANON $24 1 payment
  4. Xofluza $20 1 payment
  5. PACS $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

192,310

Median for Preventive Medicine: 100

Drug cost

$45,279,455

Median for Preventive Medicine: $5,055

Branded share of claims

100%

Median for Preventive Medicine: 27.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 70,775 $21,818,610
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 71,758 $15,329,077
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 17,508 $5,370,752
Boostrix Tdap Diphth,pertuss(Acell),tet Vac Brand 23,521 $1,563,177
Twinrix Hepatitis A And B Vaccine/Pf Brand 5,723 $828,702
Havrix Hepatitis A Virus Vaccine/Pf Brand 946 $96,880
Gardasil 9 Hpv Vaccine 9-Valent/Pf Brand 229 $71,761
M-M-R Ii Vaccine Measles,mumps,rubella Vacc/Pf Brand 370 $41,190
Vaqta Hepatitis A Virus Vaccine/Pf Brand 378 $37,825
Adacel Tdap Diph,pertuss(Acell),tet Vac/Pf Brand 447 $29,747

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 584 Part D prescribers listed as Preventive Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Occupational Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record